低剂量地西他滨通过LKB1调节免疫性血小板减少症中髓源性抑制细胞的适应度
本研究在体外和体内分析低剂量地西他滨对免疫性血小板减少症(ITP)患者髓源性抑制细胞(MDSC)的影响。低剂量地西他滨促进MDSC生成并增强其有氧代谢和免疫抑制功能,且纠正ITP患者MDSC中低表达的肝激酶1(LKB1)。LKB1 shRNA转染几乎抵消地西他滨对受损MDSC的增强作用;被动输注地西他滨调节的MDSC较磷酸盐缓冲液调节的MDSC显著提高SCID小鼠血小板计数,而LKB1 shRNA转染MDSC后该治疗效应被消除。
要点
- 低剂量地西他滨促进ITP患者MDSC生成并增强其有氧代谢与免疫抑制功能。
- ITP患者MDSC中LKB1表达降低,地西他滨治疗可纠正该低表达。
- LKB1 shRNA转染几乎抵消地西他滨对受损MDSC的增强作用。
核心结论
- 研究提示MDSC有氧代谢受损参与ITP发病,地西他滨对MDSC代谢的调节有助于改善其免疫抑制功能,为低剂量地西他滨诱导ITP患者持续缓解提供可能机制。
研究设计与样本
- 体外和体内分析低剂量地西他滨对ITP患者MDSC的影响;将抗CD61免疫致敏脾细胞转移至严重联合免疫缺陷(SCID)小鼠诱导ITP模型。
主要发现
- 低剂量地西他滨促进MDSC生成并增强其有氧代谢和免疫抑制功能。
- ITP患者MDSC中肝激酶1(LKB1)表达较低,地西他滨治疗可纠正。
- LKB1 shRNA转染有效阻断MDSC功能,并几乎抵消地西他滨对受损MDSC的增强作用。
- 被动输注地西他滨调节的MDSC较磷酸盐缓冲液调节的MDSC显著提高SCID小鼠血小板计数。
- 转染LKB1 shRNA的MDSC输注后,地西他滨缓解血小板减少的治疗效应被消除。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myeloid-derived suppressor cells (MDSCs) are heterogeneous immature cells and natural inhibitors of adaptive immunity. Metabolic fitness of MDSCs is fundamental for its suppressive activity toward effector T cells. Our previous studies showed that the number and inhibitory function of MDSCs were impaired in patients with immune thrombocytopenia (ITP) compared with healthy controls. In this study, we analyzed the effects of decitabine on MDSCs from patients with ITP, both in vitro and in vivo. We found that low-dose decitabine promoted the generation of MDSCs and enhanced their aerobic metabolism and immunosuppressive functions. Lower expression of liver kinase 1 (LKB1) was found in MDSCs from patients with ITP, which was corrected by decitabine therapy. LKB1 short hairpin RNA (shRNA) transfection effectively blocked the function of MDSCs and almost offset the enhanced effect of decitabine on impaired MDSCs. Subsequently, anti-CD61 immune-sensitized splenocytes were transferred into severe combined immunodeficient (SCID) mice to induce ITP in murine models. Passive transfer of decitabine-modulated MDSCs significantly raised platelet counts compared with that of phosphate buffered saline-modulated MDSCs. However, when LKB1 shRNA-transfected MDSCs were transferred into SCID mice, the therapeutic effect of decitabine in alleviating thrombocytopenia was quenched. In conclusion, our study suggests that the impaired aerobic metabolism of MDSCs is involved in the pathogenesis of ITP, and the modulatory effect of decitabine on MDSC metabolism contributes to the improvement of its immunosuppressive function. This provides a possible mechanism for sustained remission elicited by low-dose decitabine in patients with ITP.
引用
- Ni X, Wang L, Wang H, et al. Low-dose decitabine modulates myeloid-derived suppressor cell fitness via LKB1 in immune thrombocytopenia. Blood. 2022. PMID: 36037415. doi:10.1182/blood.2022016029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。